United Laboratories International Holdings Ltd

UNJ

Company Profile

  • Business description

    United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.

  • Contact

    No. 6 Fuk Wang Street
    Yuen Long Industrial Estate
    New Territories
    Hong Kong
    HKG

    T: +852 26871033

    http://www.tul.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    17,400

Stocks News & Analysis

stocks

Weekly earnings wrap: Last week’s winners & losers

A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks

Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount

Strong fourth quarter earnings.
stocks

Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies

We’ve raised our fair value estimate of Lilly stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.60104.20-1.15%
CAC 408,224.7813.39-0.16%
DAX 4024,534.1243.060.18%
Dow JONES (US)49,053.22448.08-0.91%
FTSE 10010,304.764.46-0.04%
HKSE26,559.95325.29-1.21%
NASDAQ22,540.59363.99-1.59%
Nikkei 22554,253.68435.640.81%
NZX 50 Index13,444.0223.27-0.17%
S&P 5006,821.7261.00-0.89%
S&P/ASX 2008,708.8096.70-1.10%
SSE Composite Index4,065.5810.33-0.25%

Market Movers